Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials

UCLA's Jonsson Comprehensive Cancer Center

UCLA's Jonsson Comprehensive Cancer Center
JCCC: A Comprehensive Cancer Center
JCCC Member Directory
Calendar
Contact Us
Map and Directions to JCCC
Social Media
Connect via Mobile
Privacy Practices
 
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Jay V. Vadgama, Ph.D.
Jay V. Vadgama, Ph.D.

Affiliation(s):

Professor, David Geffen School of Medicine at UCLA
Professor of Medicine, Charles Drew University of Medicine and Science
Chief, Division of Cancer Research and Training, Charles Drew University of Medicine and Science
Endowed Chair in Cancer Research, Charles Drew University of Medicine and Science
Director, Center to Eliminate Cancer Health Disparities, Department of Internal Medicine, Charles Drew University of Medicine and Science
Member, JCCC Signal Transduction and Therapeutics Program Area

Contact Information:

Phone:
(323) 563-4853
Email:
jayvadgama@cdrewu.edu

Scientific Interest(s):

Dr. Jay Vadgama has extensive experience in conducting oncology research that integrates clinical, basic and community-based studies. The outcome of these efforts has resulted in the development of translational cancer research at Charles Drew University (CDU). Research programs in his division focus on:
  1. genetics and epigenetics of breast, colorectal and prostate cancers
  2. identification of cellular and molecular markers and novel genes for early detection, prevention and management of breast, colorectal cancer and prostate cancers
  3. mechanisms associated with bone metastasis from breast cancer
  4. role of mismatch repair proteins and microsatellite instability in colorectal cancer in minority populations
  5. identification and characterization of normal and cancer stem cells in breast and prostate cancers that contribute to drug resistance
  6. cancer outreach and prevention studies.
Vadgama has developed an extensive tissue repository program with detailed clinical follow-up data on African American and Latina populations. He is principal investigator of several center grants in cancer at CDU in partnership with UCLA.

Selected Cancer-Related Publications:

Wu Y, Shang X, Sarkissyan M, Slamon D, Vadgama JV. FOXO1A is a target for HER2-overexpressing breast tumors. Cancer Res. 2010 Jul 1;70(13):5475-85. Epub 2010 Jun 15.

Wu Y, Alvarez M, Slamon DJ, Koeffler P, Vadgama JV. Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation. BMC Cancer. 2010 Feb 4;10:32.

Yin D, Chen W, O'Kelly J, Lu D, Ham M, Doan NB, Xie D, Wang C, Vadgama J, Said JW, Black KL, Koeffler HP. Connective tissue growth factor associated with oncogenic activities and drug resistance in glioblastoma multiforme. Int J Cancer. 2010 Nov 15;127(10):2257-67.

Mishra DK, Chen Z, Wu Y, Sarkissyan M, Koeffler HP, Vadgama JV. Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells. Mol Cancer Ther. 2010 Jan;9(1):33-45. Epub 2010 Jan 6.

Wu Y, Mohamed H, Chillar R, Ali I, Clayton S, Slamon D, Vadgama JV. Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Res. 2008;10(1):R3. Epub 2008 Jan 10.